Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Pharmacol Res Perspect ; 10(2): e00938, 2022 04.
Article in English | MEDLINE | ID: mdl-35194979

ABSTRACT

An excess phosphate burden in renal disease has pathological consequences for bone, kidney, and heart. Therapies to decrease intestinal phosphate absorption have been used to address the problem, but with limited success. Here, we describe the in vivo effects of a novel potent inhibitor of the intestinal sodium-dependent phosphate cotransporter NPT2b, LY3358966. Following treatment with LY3358966, phosphate uptake into plasma 15 min following an oral dose of radiolabeled phosphate was decreased 74% and 22% in mice and rats, respectively, indicating NPT2b plays a much more dominant role in mice than rats. Following the treatment with LY3358966 and radiolabeled phosphate, mouse feces were collected for 48 h to determine the ability of LY3358966 to inhibit phosphate absorption. Compared to vehicle-treated animals, there was a significant increase in radiolabeled phosphate recovered in feces (8.6% of the dose, p < .0001). Similar studies performed in rats also increased phosphate recovered in feces (5.3% of the dose, p < .05). When used in combination with the phosphate binder sevelamer in rats, there was a further small, but not significant, increase in fecal phosphate. In conclusion, LY3358966 revealed a more prominent role for NPT2b on acute intestinal phosphate uptake into plasma in mice than rats. However, the modest effects on total intestinal phosphate absorption observed in mice and rats with LY3359866 when used alone or in combination with sevelamer highlights the challenge to identify new more effective therapeutic targets and/or drug combinations to treat the phosphate burden in patients with renal disease.


Subject(s)
Intestinal Absorption , Phosphates/metabolism , Sodium-Phosphate Cotransporter Proteins, Type IIb/antagonists & inhibitors , Animals , CHO Cells , Chelating Agents/administration & dosage , Chelating Agents/pharmacology , Cricetulus , Male , Mice , Mice, Inbred C57BL , Rats , Rats, Sprague-Dawley , Sevelamer/administration & dosage , Sevelamer/pharmacology , Sodium-Phosphate Cotransporter Proteins, Type IIb/metabolism , Species Specificity
2.
Toxins (Basel) ; 13(10)2021 09 27.
Article in English | MEDLINE | ID: mdl-34678981

ABSTRACT

P-cresyl sulfate and indoxyl sulfate are strongly associated with cardiovascular events and all-cause mortality in chronic kidney disease (CKD). This randomized controlled trial was conducted to compare the effects between sevelamer and calcium carbonate on protein-bound uremic toxins in pre-dialysis CKD patients with hyperphosphatemia. Forty pre-dialysis CKD patients with persistent hyperphosphatemia were randomly assigned to receive either 2400 mg of sevelamer daily or 1500 mg of calcium carbonate daily for 24 weeks. A significant decrease of total serum p-cresyl sulfate was observed in sevelamer therapy compared to calcium carbonate therapy (mean difference between two groups -5.61 mg/L; 95% CI -11.01 to -0.27 mg/L; p = 0.04). There was no significant difference in serum indoxyl sulfate levels (p = 0.36). Sevelamer had effects in terms of lowering fibroblast growth factor 23 (p = 0.01) and low-density lipoprotein cholesterol levels (p = 0.04). Sevelamer showed benefits in terms of retarding CKD progression. Changes in vascular stiffness were not found in this study.


Subject(s)
Chelating Agents/administration & dosage , Cresols/blood , Hyperphosphatemia/drug therapy , Indican/blood , Sevelamer/administration & dosage , Sulfuric Acid Esters/blood , Calcium Carbonate/administration & dosage , Female , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/drug therapy , Uremic Toxins/blood
3.
J Clin Pharm Ther ; 46(2): 369-372, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33037822

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Sevelamer is an insoluble polymer indicated for the management of hyperphosphatemia in patients with chronic kidney disease (CKD). The package inserts for both tablet formulations recommend the tablets be administered whole. Due to whole tablets being sometimes inadvertently crushed and the significantly increased cost of sevelamer packets, we evaluated the safety and feasibility of crushed sevelamer tablets for enteral feeding tube administration. METHODS: A single-centre retrospective chart review was performed. All adult ICU patients prescribed sevelamer carbonate between 1 January 2015 and 31 July 2019 were included if they received at least one dose of a sevelamer tablet or packet, whereas they had an enteral feeding tube in place. The primary outcome was the incidence of an obstructed enteral feeding tube or need for replacement, as defined as the number of occurrences over the total numbers of doses administered. The secondary outcome was the change in phosphorus levels from time of sevelamer initiation to discontinuation or patient discharge. RESULTS: A total of 14 obstructions were reported, four in the tablet arm and ten in the packet arm (0.4% tablet arm, 0.5% packet arm; P = .5931). Of these, four (29%) required tube replacement and were followed by sevelamer discontinuation. Two (14%) were documented to be due to increased tube feeds and esomeprazole. Six (43%) cases required tube replacement, but no issues arose upon continuation. Only one of the obstructions resulted in a recurrent tube occlusion. WHAT IS NEW AND CONCLUSION: Sevelamer tablets may be crushed and administered via enteral feeding tubes, provided clear instruction on tablet preparation is included. Oral administration in dysphagic patients requires further evaluation with clear protocols for preparation and administration.


Subject(s)
Chelating Agents/administration & dosage , Enteral Nutrition/methods , Hyperphosphatemia/drug therapy , Hyperphosphatemia/etiology , Renal Insufficiency, Chronic/complications , Sevelamer/administration & dosage , Chelating Agents/therapeutic use , Drug Administration Routes , Humans , Intensive Care Units , Retrospective Studies , Sevelamer/therapeutic use
4.
Nephron ; 144(9): 428-439, 2020.
Article in English | MEDLINE | ID: mdl-32585670

ABSTRACT

INTRODUCTION: Control of hyperphosphatemia in patients on dialysis remains a major challenge. OBJECTIVE: This study evaluated predictors of serum phosphorus (sP) control among dialysis patients treated with noncalcium, oral phosphate binder therapy in a phase 3 clinical trial. METHODS: Post hoc analyses were performed using data for patients with hyperphosphatemia who received 52 weeks of treatment with sucroferric oxyhydroxide (SFOH) or sevelamer carbonate (sevelamer). Patients were categorized into those who achieved sP control (n = 302; defined as sP ≤ 5.5 mg/dL at week 52), and those with uncontrolled sP (n = 195; sP >5.5 mg/dL at week 52). Because SFOH and sevelamer have previously demonstrated similar effects on chronic kidney disease-mineral-bone disorder parameters in this study, the treatment groups were pooled. RESULTS: Average age at baseline was higher among sP-controlled versus sP-uncontrolled patients (56.9 vs. 53.4 years; p = 0.005). Baseline sP levels were significantly lower among sP-controlled versus sP-uncontrolled patients (7.30 vs. 7.85 mg/dL; p < 0.001), and sP reductions from baseline were significantly greater in the sP-controlled group (-2.89 vs. -0.99 mg/dL at week 52; p < 0.001). Logistic regression analysis identified higher baseline sP levels (odds ratio [OR] = 0.86, 95% confidence interval [CI]: 0.765-0.960), no concomitant active vitamin D therapy use (OR = 0.51, 95% CI: 0.328-0.804), and higher body mass index at baseline (OR = 0.96, 95% CI: 0.937-0.992) as significant predictors of uncontrolled sP. CONCLUSION: This analysis indicates that sP control may be more challenging in younger patients with high sP levels. Closer monitoring and management of serum phosphorus levels may be required in this population.


Subject(s)
Ferric Compounds/therapeutic use , Hyperphosphatemia/blood , Hyperphosphatemia/drug therapy , Phosphorus/blood , Sevelamer/therapeutic use , Sucrose/therapeutic use , Adult , Age Factors , Aged , Calcimimetic Agents/administration & dosage , Chelating Agents/administration & dosage , Chelating Agents/adverse effects , Chelating Agents/therapeutic use , Drug Combinations , Female , Ferric Compounds/administration & dosage , Ferric Compounds/adverse effects , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Humans , Logistic Models , Male , Middle Aged , Parathyroid Hormone/blood , Renal Dialysis/adverse effects , Renal Dialysis/methods , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/therapy , Sevelamer/administration & dosage , Sevelamer/adverse effects , Sucrose/administration & dosage , Sucrose/adverse effects , Vitamin D/administration & dosage
5.
FASEB J ; 34(5): 7089-7102, 2020 05.
Article in English | MEDLINE | ID: mdl-32275114

ABSTRACT

There is compelling evidence implicating intestinal permeability in the pathogenesis of nonalcoholic steatohepatitis (NASH), but the underlying mechanisms remain poorly understood. Here we examined the role of bile acids (BA) in western diet (WD)-induced loss of colonic epithelial barrier (CEB) function in mice with a genetic impairment in intestinal epithelial barrier function, junctional adhesion molecule A knockout mice, F11r-/- . WD-fed knockout mice developed severe NASH, which was associated with increased BA concentration in the cecum and loss of CEB function. Analysis of cecal BA composition revealed selective increases in primary unconjugated BAs in the WD-fed mice, which correlated with increased abundance of microbial taxa linked to BA metabolism. In vitro permeability assays revealed that chenodeoxycholic acid (CDCA), which was elevated in the cecum of WD-fed mice, increased paracellular permeability, while the BA-binding resin sevelamer hydrochloride protected against CDCA-induced loss of barrier function. Sequestration of intestinal BAs by in vivo delivery of sevelamer to WD-fed knockout mice attenuated colonic mucosal inflammation and improved CEB. Sevelamer also reduced hepatic inflammation and fibrosis, and improved metabolic derangements associated with NASH. Collectively, these findings highlight a hitherto unappreciated role for BAs in WD-induced impairment of the intestinal epithelial barrier in NASH.


Subject(s)
Bile Acids and Salts/metabolism , Colon/metabolism , Diet, Western/adverse effects , Non-alcoholic Fatty Liver Disease/metabolism , Animals , Caco-2 Cells , Cell Adhesion Molecules/deficiency , Cell Adhesion Molecules/genetics , Colon/pathology , Disease Models, Animal , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/pathology , Permeability , Receptors, Cell Surface/deficiency , Receptors, Cell Surface/genetics , Sevelamer/administration & dosage
6.
Buenos Aires; IECS; mar. 2020.
Non-conventional in Spanish | BRISA/RedTESA | ID: biblio-1348890

ABSTRACT

CONTEXTO CLÍNICO: La enfermedad renal crónica (ERC) se asocia a una elevada morbimortalidad; siendo las patologías cardiovasculares una de las causas más importante de muerte sumado a la existencia de múltiples factores de riesgo no clásicos inherentes a la propia enfermedad, como la anemia, albuminuria, inflamación, estrés oxidativo, malnutrición, entre otros. Las alteraciones del metabolismo óseo-mineral hoy en día son consideradas un componente importante de estos factores de riesgo cardiovascular no tradicionales en los pacientes con ERC. La hiperfosfatemia y el aumento de factor de crecimiento fibroblástico (FGF-23) son los parámetros más importantes, por encima incluso de la hormona paratiroidea (PTH), calcio plasmático (CA) o fosfatasa alcalina (FAL) que se asocian a la mortalidad de pacientes dializados. TECNOLOGÍA: El carbonato sevelamer es una molécula con numerosas aminas separadas por un carbono del esqueleto del polímero que se cargan parcialmente de protones en el estómago. Estas aminas protonadas se unen en el intestino a iones con carga negativa como el fósforo de la dieta disminuyendo así la absorción del mismo. OBJETIVO: El objetivo del presente informe es evaluar la evidencia disponible acerca de la eficacia, seguridad y aspectos relacionados a las políticas de cobertura del uso de carbonato de sevelamer para control de hiperfosfatemia en la insuficiencia renal crónica. MÉTODOS: Se realizó una búsqueda en las principales bases de datos bibliográficas, en buscadores genéricos de internet, y financiadores de salud. Se priorizó la inclusión de revisiones sistemáticas (RS), ensayos clínicos controlados aleatorizados (ECAs), evaluaciones de tecnologías sanitarias (ETS), evaluaciones económicas, guías de práctica clínica (GPC) y políticas de cobertura de diferentes sistemas de salud. RESULTADOS: Se incluyeron dos RS, tres GPC, dos evaluaciones económicas y 14 informes de políticas de cobertura para el uso de carbonato de sevelamer en hiperfosfatemia para ERC. CONCLUSIONES: Evidencia de baja calidad sugiere que el uso de carbonato de sevelamer reduciría la mortalidad por todas las causas a corto plazo, y disminuiría la hiperfosfatemia en pacientes que requieren reemplazo de la función renal y que no han respondido a terapia con quelantes cálcicos. Evidencia de muy baja calidad no permite establecer el efecto sobre la mortalidad cardiovascular ni que alguno de los quelantes de fósforo sea superior a alternativas en cuanto a disminuir los niveles de fósforo o presentar menor frecuencia de efectos adversos como constipación o intolerancia digestiva. Las distintas guías de práctica clínica relevadas, como la guía KDIGO, así como otras latinoamericanas y argentinas recomiendan en forma genérica el uso de quelantes no cálcicos en alguna de las siguientes situaciones: pacientes que hubieren alcanzado dosis máximas de quelante cálcico con niveles de fósforo no controlado; pacientes con calcemia corregida mayor de 10 mg/dL a pesar de estar dializando con un calcio de 2,5 mEq/L; pacientes con una hiperfosfatemia persistente y sostenida mayor o igual a 6,5 mg/dL; pacientes con calcificaciones vasculares y/o calcifilaxis. En pacientes en estadios pre-dialíticos sólo debería indicarse en el caso de hiperfosfatemia progresiva o persistente por más de tres meses que no responde, y no para prevenir hiperfosfatemia. Diversos financiadores de salud estadounidenses, europeos, latinoamericanos y argentinos cubren el carbonato de sevelamer para el tratamiento de hiperfosfatemia sin establecer criterios definidos en algunos casos y en otros según las recomendaciones de distintas guías de práctica clínica.


Subject(s)
Humans , Renal Insufficiency, Chronic/pathology , Hyperphosphatemia/prevention & control , Sevelamer/administration & dosage , Treatment Outcome , Cost-Benefit Analysis
7.
Drugs ; 79(8): 855-862, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31062264

ABSTRACT

BACKGROUND: Hyperphosphatemia control is a major issue in hemodialysis patients. Both sevelamer and nicotinamide are prescribed for this purpose. In addition, they exert pleiotropic effects such as an improvement of inflammatory status and potentially enhanced clearance of uremic toxins. In the present secondary analysis of the NICOREN trial, we investigated the impact of sevelamer and nicotinamide on uremic toxins, toxin precursors, and endotoxemia in chronic hemodialysis patients. METHODS: Circulating uremic toxins (including phenylacetylglutamine, trimethylamine-N-oxide, p-cresyl sulfate, indoxyl sulfate, kynurenine, hippuric acid, indole-3-acetic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, kynurenic acid, and p-cresyl glucuronide) and precursors were measured by ultra-performance liquid chromatography-tandem mass spectrometry, and urea, uric acid, phosphate, C-reactive protein, and intact parathyroid hormone by routine biochemistry methods. Serum endotoxin (evaluated by lipopolysaccharide levels) and C-terminal fibroblast growth factor-23 levels were measured using enzyme-linked immunosorbent assay kits. RESULTS: One hundred hemodialysis patients were randomized to receive either nicotinamide or sevelamer treatment. Among them, 63% were male, mean (± standard deviation) age was 65 ± 14 years, 47% had diabetes mellitus, and 51% had a history of cardiovascular disease. In the sevelamer group, but not the nicotinamide group, serum levels of urea, uric acid, and fibroblast growth factor-23 were significantly reduced after 6 months of treatment. The other circulating uremic toxins and toxin precursors remained unchanged in response to either phosphate-lowering agent. Sevelamer treatment led to a marked decrease in serum lipopolysaccharide (p < 0.001) whereas nicotinamide treatment induced an only modest decrease of borderline significance (p = 0.057). There was no change in C-reactive protein levels. CONCLUSION: In contrast to sevelamer, nicotinamide did not reduce circulating levels of low-molecular-weight uremic toxins other than phosphate, and neither agent reduced circulating uremic toxins of high-molecular-weight or protein-bound toxins. Sevelamer, but not nicotinamide, reduced serum endotoxin levels. Despite no change in serum C-reactive protein, the endotoxin-lowering effect of sevelamer may help to attenuate the inflammatory status of patients with chronic kidney disease.


Subject(s)
Endotoxemia/drug therapy , Endotoxins/blood , Niacinamide/administration & dosage , Renal Insufficiency, Chronic/drug therapy , Sevelamer/administration & dosage , Aged , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Humans , Hyperphosphatemia/drug therapy , Male , Middle Aged , Phosphates/blood , Renal Dialysis , Uric Acid/blood
8.
Toxins (Basel) ; 11(5)2019 05 17.
Article in English | MEDLINE | ID: mdl-31109001

ABSTRACT

High serum levels of gut-derived uremic toxins, especially p-cresyl sulfate (pCS), indoxyl sulfate (IS) and indole acetic acid (IAA), have been linked to adverse outcomes in patients with chronic kidney disease (CKD). Sevelamer carbonate could represent an interesting option to limit the elevation of gut-derived uremic toxins. The aim of the present study was to evaluate the adsorptive effect of sevelamer carbonate on different gut-derived protein-bound uremic toxins or their precursors in vitro, and its impact on the serum levels of pCS, IS and IAA in patients with CKD stage 3b/4. For the in vitro experiments, IAA, p-cresol (precursor of pCS) and indole (precursor of IS), each at a final concentration of 1 or 10 µg/mL, were incubated in centrifugal 30 kDa filter devices with 3 or 15 mg/mL sevelamer carbonate in phosphate-buffered saline at a pH adjusted to 6 or 8. Then, samples were centrifuged and free uremic toxins in the filtrates were analyzed. As a control experiment, the adsorption of phosphate was also evaluated. Additionally, patients with stage 3b/4 CKD (defined as an eGFR between 15 and 45 mL/min per 1.73 m2) were included in a multicenter, double-blind, placebo-controlled, randomized clinical trial. The participants received either placebo or sevelamer carbonate (4.8 g) three times a day for 12 weeks. The concentrations of the toxins and their precursors were measured using a validated high-performance liquid chromatography method with a diode array detector. In vitro, regardless of the pH and concentration tested, sevelamer carbonate did not show adsorption of indole and p-cresol. Conversely, with 10 µg/mL IAA, use of a high concentration of sevelamer carbonate (15 mg/mL) resulted in a significant toxin adsorption both at pH 8 (mean reduction: 26.3 ± 3.4%) and pH 6 (mean reduction: 38.7 ± 1.7%). In patients with CKD stage 3b/4, a 12-week course of treatment with sevelamer carbonate was not associated with significant decreases in serum pCS, IS and IAA levels (median difference to baseline levels: -0.12, 0.26 and -0.06 µg/mL in the sevelamer group vs. 1.97, 0.38 and 0.05 µg/mL in the placebo group, respectively). Finally, in vitro, sevelamer carbonate was capable of chelating a gut-derived uremic toxin IAA but not p-cresol and indole, the precursors of pCS and IS in the gut. In a well-designed clinical study of patients with stage 3b/4 CKD, a 12-week course of treatment with sevelamer carbonate was not associated with significant changes in the serum concentrations of pCS, IS and IAA.


Subject(s)
Chelating Agents/administration & dosage , Cresols/blood , Indican/blood , Indoleacetic Acids/blood , Renal Insufficiency, Chronic/drug therapy , Sevelamer/administration & dosage , Sulfuric Acid Esters/blood , Toxins, Biological/blood , Adsorption , Aged , Chelating Agents/chemistry , Cresols/chemistry , Double-Blind Method , Female , Gastrointestinal Tract/chemistry , Gastrointestinal Tract/metabolism , Humans , Indican/chemistry , Indoleacetic Acids/chemistry , Male , Middle Aged , Renal Insufficiency, Chronic/blood , Sevelamer/chemistry , Sulfuric Acid Esters/chemistry , Uremia
9.
Am J Kidney Dis ; 74(3): 338-350, 2019 09.
Article in English | MEDLINE | ID: mdl-31027883

ABSTRACT

RATIONALE & OBJECTIVE: Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers. We investigated whether the phosphate binder sevelamer carbonate may enhance the antiproteinuric effect of RAS inhibitors in patients with CKD. STUDY DESIGN: Phase 2, randomized, controlled, open-label, crossover trial. SETTING & PARTICIPANTS: Between November 2013 and December 2014, we enrolled 53 patients with CKD with estimated glomerular filtration rates (eGFRs)>15mL/min/1.73m2 and residual proteinuria with protein excretion≥0.5g/24h despite maximal tolerated ramipril and/or irbesartan therapy from 2 nephrology units in Italy. INTERVENTION: After stratification by serum phosphate level, ≤4 or>4mg/dL, patients were randomly assigned to 3 months of sevelamer (1,600mg thrice daily) treatment followed by 3 months without sevelamer separated by a 1-month washout period or 3 months without sevelamer followed by 3 months with sevelamer, also separated by a 1-month washout period. OUTCOMES: The primary outcome was 24-hour proteinuria (n=49patients). Secondary outcomes included measured GFR (using iohexol plasma clearance), office blood pressure (BP), serum lipid levels, levels of inflammation and bone metabolism biomarkers, urinary electrolyte levels, and arterial stiffness. RESULTS: Changes in proteinuria during the 3-month treatment with (from 1.36 [IQR, 0.77-2.51] to 1.36 [IQR, 0.77-2.60] g/24h) or without (from 1.36 [IQR, 0.99-2.38] to 1.48 [IQR, 0.81-2.77] g/24h) sevelamer were similar (P=0.1). Sevelamer reduced urinary phosphate excretion without affecting serum phosphate levels. Sevelamer reduced C-reactive protein (CRP), glycated hemoglobin, and total and low-density lipoprotein cholesterol levels and increased high-density lipoprotein cholesterol levels without affecting levels of office BP, measured GFR, fibroblast growth factor 23, klotho, intact parathyroid hormone, serum vitamin D, or other urinary electrolytes. Results were similar in the low- and high-phosphate groups. Sevelamer was well tolerated. Adverse events were comparable between treatment periods. One case of transient hypophosphatemia was observed during treatment with sevelamer. LIMITATIONS: Short treatment duration, lower pretreatment proteinuria than expected. CONCLUSIONS: 3-month sevelamer treatment did not reduce proteinuria in patients with CKD on maximal RAS blockade. Amelioration of inflammation and dyslipidemia with sevelamer treatment raises the possibility that it may confer benefit in patients with CKD beyond reduction of proteinuria. FUNDING: Sanofi (Milan, Italy). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01968759.


Subject(s)
Hyperphosphatemia/drug therapy , Irbesartan , Proteinuria/prevention & control , Ramipril , Renal Insufficiency, Chronic , Sevelamer , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Chelating Agents/administration & dosage , Chelating Agents/adverse effects , Cross-Over Studies , Drug Monitoring/methods , Drug Therapy, Combination/methods , Female , Fibroblast Growth Factor-23 , Glomerular Filtration Rate , Humans , Hyperphosphatemia/etiology , Irbesartan/administration & dosage , Irbesartan/adverse effects , Male , Middle Aged , Phosphates/blood , Proteinuria/etiology , Ramipril/administration & dosage , Ramipril/adverse effects , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/drug therapy , Renin-Angiotensin System/drug effects , Sevelamer/administration & dosage , Sevelamer/adverse effects , Treatment Outcome
10.
Expert Rev Pharmacoecon Outcomes Res ; 19(3): 287-298, 2019 06.
Article in English | MEDLINE | ID: mdl-30664365

ABSTRACT

INTRODUCTION: End-stage renal disease is associated with significant comorbidity and mortality. Among its implications, hyperphosphatemia constitutes a consistent and independent risk factor. The use of benchmark treatment, low-cost calcium-based binders declined due to a potential calcification effect on coronary arteries. AREAS COVERED: Given the increasing prevalence of end-stage renal disease and the high cost of hyperphosphatemia's new primary modality, the non-calcium based phosphate binders, we set-off to systematically assess the economic evaluations of non-calcium containing phosphate binders, sevelamer and lanthanum. The study was performed based on a systematic review of the economic evaluations of sevelamer and lanthanum. The cost-effectiveness profile of the two non-calcium-containing Phosphate Binders compared to calcium-based phosphate binders depends on several factors such as future dialysis costs, utility values, age, survival, and phosphorus levels. EXPERT OPINION: The comparison between the two agents is rather inconclusive; nevertheless, current review suggests that non-calcium-based phosphate binders may yield a positive cost-effectiveness ratio in patients with inadequate phosphorus management and patient with longer life-expectancy. It is crucial that the literature is endowed with more data, specifically on survival, future dialysis costs, and calcification.


Subject(s)
Hyperphosphatemia/drug therapy , Lanthanum/administration & dosage , Sevelamer/administration & dosage , Chelating Agents/administration & dosage , Chelating Agents/economics , Cost-Benefit Analysis , Humans , Hyperphosphatemia/economics , Kidney Failure, Chronic/economics , Kidney Failure, Chronic/therapy , Lanthanum/economics , Life Expectancy , Renal Dialysis/economics , Sevelamer/economics
12.
Value Health ; 21(3): 318-325, 2018 03.
Article in English | MEDLINE | ID: mdl-29566839

ABSTRACT

BACKGROUND: Phosphate binders are used to treat hyperphosphatemia among patients with chronic kidney disease (CKD). OBJECTIVES: To conduct an economic evaluation comparing calcium-free binders sevelamer and lanthanum with calcium-based binders for patients with CKD. METHODS: Effectiveness data were obtained from a recent meta-analysis of randomized trials. Effectiveness was measured as life-years gained and translated to quality-adjusted life-years (QALYs) using utility weights from the literature. A Markov model consisting of non-dialysis-dependent (NDD)-CKD, dialysis-dependent (DD)-CKD, and death was developed to estimate the incremental costs and effects of sevelamer and lanthanum versus those of calcium-based binders. A lifetime horizon was used and both costs and effects were discounted at 1.5%. All costs are presented in 2015 Canadian dollars from the Canadian public payer perspective. Results of probabilistic sensitivity analysis were presented using cost-effectiveness acceptability curves. Sensitivity analyses were conducted for risk pooling methods, omission of dialysis costs, and persistence of drug effects on mortality. RESULTS: Sevelamer resulted in an incremental cost-effectiveness ratio of $106,522/QALY for NDD-CKD and $133,847/QALY for DD-CKD cohorts. Excluding dialysis costs, sevelamer was cost-effective in the NDD-CKD cohort ($5,847/QALY) and the DD-CKD cohort ($11,178/QALY). Lanthanum was dominated regardless of whether dialysis costs were included. CONCLUSIONS: Existing evidence does not clearly support the cost-effectiveness of non-calcium-containing phosphate binders (sevelamer and lanthanum) relative to calcium-containing phosphate binders in DD-CKD patients. Our study suggests that sevelamer may be cost-effective before dialysis onset. Because of the remaining uncertainty in several clinically relevant outcomes over time in DD-CKD and NDD-CKD patients, further research is encouraged.


Subject(s)
Calcium Carbonate/economics , Cost-Benefit Analysis/methods , Hyperphosphatemia/economics , Lanthanum/economics , Renal Insufficiency, Chronic/economics , Sevelamer/economics , Adult , Aged , Calcium Carbonate/administration & dosage , Chelating Agents/administration & dosage , Chelating Agents/economics , Female , Humans , Hyperphosphatemia/drug therapy , Hyperphosphatemia/epidemiology , Lanthanum/administration & dosage , Male , Middle Aged , Randomized Controlled Trials as Topic/economics , Randomized Controlled Trials as Topic/methods , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/epidemiology , Sevelamer/administration & dosage
13.
PLoS One ; 12(7): e0180430, 2017.
Article in English | MEDLINE | ID: mdl-28704404

ABSTRACT

The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them an adenine-containing diet for four weeks. They were also freely fed a diet that contained PA21 (0.5, 1.5, and 5%), sevelamer hydrochloride (0.6 and 2%) or lanthanum carbonate hydrate (0.6 and 2%) for four weeks. Blood biochemical parameters were measured and bone histomorphometry was performed for femurs, which were isolated after drug treatment. Serum phosphorus and parathyroid hormone (PTH) levels were higher in the CRF rats. Administration of phosphate binders for four weeks decreased serum phosphorus and PTH levels in a dose-dependent manner and there were significant decreases in the AUC0-28 day of these parameters in 5% PA21, 2% sevelamer hydrochloride, and 2% lanthanum carbonate hydrate groups compared with that in the CRF control group. Moreover, osteoid volume improved significantly in 5% of the PA21 group, and fibrosis volume and cortical porosity were ameliorated in 5% PA21, 2% sevelamer hydrochloride, and 2% lanthanum carbonate hydrate groups. These results suggest that PA21 is effective against hyperphosphatemia, secondary hyperparathyroidism, and bone abnormalities in CKD-MBD as sevelamer hydrochloride and lanthanum carbonate hydrate are, and that PA21 is a new potential alternative to phosphate binders.


Subject(s)
Chronic Kidney Disease-Mineral and Bone Disorder/diet therapy , Ferric Compounds/administration & dosage , Kidney Failure, Chronic/chemically induced , Lanthanum/administration & dosage , Sevelamer/administration & dosage , Adenine/adverse effects , Animals , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Ferric Compounds/pharmacology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/metabolism , Lanthanum/pharmacology , Male , Parathyroid Hormone/blood , Phosphorus/blood , Rats , Sevelamer/pharmacology , Treatment Outcome
14.
Nephrol Ther ; 13 Suppl 1: S103-S108, 2017 Apr.
Article in French | MEDLINE | ID: mdl-28577730

ABSTRACT

International guidelines suggest lowering elevated phosphorus level to the normal range in patients on dialysis. Among the phosphate-lowering strategies, phosphate binder is frequently used in addition to dietary phosphate restriction and an adequate dialysis strategy. However, serum phosphate concentration higher than 1.78mmol/L is observed in more than 40% of patients justifying the quest for new drugs. Sucroferric oxyhydroxide is one of the new iron-based agents and is available in France since May 2016. A recent international multicentre study showed this new drug to be as efficacious and non-inferior to sevelamer carbonate in magnitude of serum phosphate control. The serum phosphorus-lowering effect was maintained over 1year. When compared to carbonate sevelamer, the pill-burden was half with sucroferric oxyhydroxide because of its high phosphate binding capacity. As previously shown by experimental studies, no risk of iron accumulation was observed since iron absorption is negligible. Discolored feces and diarrhea were fairly frequent side effects. When diarrhea subsides, the tolerability of this new phosphate binder is excellent on a long-term basis.


Subject(s)
Chelating Agents/administration & dosage , Ferric Compounds/administration & dosage , Hyperphosphatemia/therapy , Renal Dialysis , Sevelamer/administration & dosage , Sucrose/administration & dosage , Drug Combinations , Evidence-Based Medicine , Guidelines as Topic , Humans , Hyperphosphatemia/etiology , Randomized Controlled Trials as Topic , Renal Dialysis/adverse effects , Treatment Outcome
15.
Nephrol Ther ; 13 Suppl 1: S95-S101, 2017 Apr.
Article in French | MEDLINE | ID: mdl-28577750

ABSTRACT

Chronic kidney disease is known to be associated with phosphate retention. The mechanisms are complex and the early increase in serum phosphate levels in chronic kidney disease is not strictly related to the dietary phosphate load or to the degree of phosphate retention. It also implicates the activity of intestinal sodium-phosphate cotransporters, the degree of bone turnover and the retention and/or phosphate release from the skeleton, and the feedback mechanisms regulating the phosphaturia. Indeed, the increase in serum phosphate levels is only a reflection of underlying complex mechanisms, and many important factors play a role including parathyroid hormone, vitamin D, fibroblast growth factor 23 (FGF23), and others. Hyperphosphatemia increases the risk of cardiovascular morbidity and mortality in chronic kidney disease as well as in subjects with normal renal function. Oral phosphate binders are prescribed in patients with chronic kidney disease and in those treated by dialysis, to prevent intestinal absorption of dietary phosphate and reduce serum phosphate. In prospective observational studies, they have been shown to decrease all-cause and cardiovascular mortality risk. However, different problems have been associated with currently available phosphate binders including the induction of a positive calcium balance and impaired outcomes with calcium-based phosphate binders or increased costs with non-calcium-based phosphate binders. Iron-based phosphate binders represent a new class of phosphate binders. The aim of this article is to provide an update review of the pathophysiological mechanisms leading and maintaining elevated serum phosphate levels in patients with chronic kidney disease and patients in dialysis, and the educational, nutritional, and therapeutic strategies that can be undertaken to control the hyperphosphatemia.


Subject(s)
Chelating Agents/administration & dosage , Hyperphosphatemia/therapy , Renal Dialysis , Renal Insufficiency, Chronic/therapy , Sevelamer/administration & dosage , Biomarkers/blood , Calcium/blood , Fibroblast Growth Factor-23 , Humans , Hyperphosphatemia/etiology , Observational Studies as Topic , Parathyroid Hormone/blood , Phosphates/blood , Renal Dialysis/methods , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/physiopathology , Treatment Outcome
16.
Clin Pharmacol Drug Dev ; 6(5): 448-456, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27654985

ABSTRACT

Tenapanor (RDX5791, AZD1722), a first-in-class small molecule with minimal systemic availability, is an inhibitor of the sodium/hydrogen exchanger isoform 3. Tenapanor acts locally in the gut, where it reduces absorption of sodium and phosphate. It is being studied in patients with chronic kidney disease requiring dialysis, who are often administered phosphate binders such as sevelamer to help control hyperphosphatemia. We investigated whether coadministration of tenapanor with phosphate binders (sevelamer or calcium-based binders) impacts the pharmacodynamic effects of tenapanor. In vitro studies suggested a binding interaction between tenapanor and sevelamer, but this did not translate into altered pharmacodynamic effects in rats. An open-label, 2-way crossover study was then conducted in healthy volunteers (NCT02346890). This showed that 4 days' treatment with tenapanor hydrochloride (15 mg twice daily) with or without sevelamer carbonate (800 mg 3 times daily) resulted in comparable 24-hour stool and urinary sodium and phosphorus levels. Stool frequency, consistency, and weight were also comparable between the treatments. These results suggest that the binding between sevelamer and tenapanor observed in vitro does not translate into altered pharmacodynamic effects in humans.


Subject(s)
Isoquinolines/administration & dosage , Phosphorus/urine , Sevelamer/administration & dosage , Sodium/urine , Sulfonamides/administration & dosage , Adult , Animals , Cross-Over Studies , Drug Administration Schedule , Drug Evaluation, Preclinical , Drug Interactions , Female , Healthy Volunteers , Humans , Isoquinolines/pharmacology , Male , Middle Aged , Random Allocation , Rats , Sevelamer/pharmacology , Sulfonamides/pharmacology
17.
Nephrol Dial Transplant ; 32(5): 870-879, 2017 May 01.
Article in English | MEDLINE | ID: mdl-27190329

ABSTRACT

BACKGROUND: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease. METHODS: The NICOREN multicentre, open-label and randomized study was designed to examine non-inferiority and safety of NAM when compared with sevelamer (SEV) in chronic haemodialysis patients. One hundred patients were randomized to either NAM or SEV treatment for 24 weeks. Serum biochemistry and NAM's main metabolite, N -methyl-2-pyridone-5-carboxamide (2PY), were measured to assess compliance, efficacy and safety. RESULTS: After 24 weeks, we observed a comparable decrease in serum phosphorus in the NAM and SEV treatment arms, from 2.1 ± 0.4 to 1.8 ± 0.5 and 2.3 ± 0.5 to 1.7 ± 0.5 mM (P = not significant), respectively. The criterion for non-inferiority was, however, not met due to a more limited number of patients being included than planned. Treatment discontinuation due to adverse events was 1.6 times higher in the NAM than in the SEV group with only 55% of study completers in the NAM arm versus 90% in the SEV arm. Thrombocytopenia was observed in four NAM-treated patients. Serum 2PY levels were comparable at baseline, but increased markedly in the NAM group, but not in the SEV group, at 24 weeks (P < 0.0001). CONCLUSIONS: Thus, both drugs are equally effective in lowering serum phosphorus, but patients' tolerance of NAM was largely inferior to that of SEV. Extremely high 2PY levels may contribute to NAM's side effects.


Subject(s)
Hyperphosphatemia/drug therapy , Niacinamide/administration & dosage , Phosphorus/blood , Renal Dialysis , Renal Insufficiency, Chronic/complications , Sevelamer/administration & dosage , Adult , Aged , Female , Humans , Hyperphosphatemia/etiology , Male , Middle Aged , Prospective Studies , Renal Insufficiency, Chronic/therapy
18.
Nephrology (Carlton) ; 22(4): 293-300, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27496336

ABSTRACT

AIM: We aimed to investigate the non-inferiority of PA21 (sucroferric oxyhydroxide) to sevelamer hydrochloride (sevelamer) in terms of efficacy and safety in Japanese haemodialysis patients with hyperphosphataemia. METHODS: In this Phase III, open-label, multicentre study, 213 haemodialysis patients with hyperphosphataemia were randomized to PA21 or sevelamer treatment for 12 weeks. The primary outcome was adjusted serum phosphorus concentration at the end of treatment; the non-inferiority of PA21 was confirmed if the upper limit of the two-sided 95% confidence interval (CI) is ≤0.32 mmol/L. Secondary outcomes were corrected serum calcium and intact-parathyroid hormone concentrations. Adverse events (AEs) and adverse drug reactions (ADRs) were evaluated. RESULTS: The adjusted mean serum phosphorus concentration at the end of treatment confirmed the non-inferiority of PA21 for lowering serum phosphorus compared with sevelamer (1.62 vs 1.72 mmol/L; difference, -0.11 mmol/L; 95% CI, -0.20 to -0.02 mmol/L). The mean daily tablet intake was 5.6 ± 2.6 and 18.7 ± 7.1 tablets in the PA21 and sevelamer groups, respectively. The incidences of AEs and ADRs were not significantly different between the two groups. CONCLUSION: The non-inferiority of PA21 to sevelamer was confirmed for the treatment of Japanese haemodialysis patients with hyperphosphataemia. PA21 was effective, safe, and well tolerated, while having a considerably lower pill burden than sevelamer.


Subject(s)
Chelating Agents/therapeutic use , Ferric Compounds/therapeutic use , Hyperphosphatemia/drug therapy , Phosphorus/blood , Renal Dialysis , Renal Insufficiency, Chronic/therapy , Sevelamer/therapeutic use , Sucrose/therapeutic use , Administration, Oral , Aged , Biomarkers/blood , Calcium/blood , Chelating Agents/administration & dosage , Chelating Agents/adverse effects , Drug Administration Schedule , Drug Combinations , Female , Ferric Compounds/administration & dosage , Ferric Compounds/adverse effects , Humans , Hyperphosphatemia/blood , Hyperphosphatemia/diagnosis , Hyperphosphatemia/etiology , Japan , Male , Middle Aged , Parathyroid Hormone/blood , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diagnosis , Sevelamer/administration & dosage , Sevelamer/adverse effects , Sucrose/administration & dosage , Sucrose/adverse effects , Tablets , Time Factors , Treatment Outcome
19.
Magnes Res ; 29(4): 184-190, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-27965186

ABSTRACT

Serum Mg levels are elevated in patients with renal insufficiency: harmful effects of hypomagnesemia have been reported in patients receiving hemodialysis (HD). In this cross-sectional study, which included 86 HD patients (male : female = 56:30, age 68 ± 12 years), we examined the clinical factors associated with serum Mg levels, with a focus on sevelamer, a phosphate binder widely used to control the hyperphosphatemia of HD patients. The mean serum Mg concentration among our patients was 2.48 ± 0.37 mg/dL (1.02 ± 0.15 mmol/L). Sevelamer was administered to 67 patients (77.9%) at a mean dose of 1.98 ± 1.64 g/day. Sex, diabetes mellitus, cardiovascular disease, anuria, and drugs other than sevelamer were not associated with serum Mg levels. HD duration, serum calcium, albumin, high-density lipoprotein cholesterol, normalized protein catabolic rate (nPCR), creatinine generation rate, and sevelamer dose correlated positively with serum Mg levels, whereas a negative correlation was observed for age and high-sensitivity C-reactive protein. A stepwise multiple regression analysis revealed that age, nPCR, and the dose of sevelamer were independently associated with serum Mg levels. Sevelamer and Mg have been reported to exhibit similar effects, such as an anti-inflammatory effect, inhibition of cardiovascular calcification, and decreased mortality. Therefore, the pleiotropic effects of sevelamer may be partly attributable to the increase in serum Mg levels caused by the drug itself.


Subject(s)
Magnesium/blood , Renal Dialysis , Sevelamer/pharmacology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Sevelamer/administration & dosage
20.
J Biol Chem ; 291(44): 23058-23067, 2016 10 28.
Article in English | MEDLINE | ID: mdl-27605663

ABSTRACT

Bile acid sequestrants are synthetic polymers that bind bile acids in the gut and are used to treat dyslipidemia and hyperphosphatemia. Recently, these agents have been reported to lower blood glucose and increase insulin sensitivity by altering bile acid signaling pathways. In this study, we assessed the efficacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD). We also analyzed how sevelamer alters inflammation and bile acid signaling in NAFLD livers. Mice were fed a low-fat or Western diet for 12 weeks followed by a diet-plus-sevelamer regimen for 2 or 12 weeks. At the end of treatment, disease severity was assessed, hepatic leukocyte populations were examined, and expression of genes involved in farnesoid X receptor (FXR) signaling in the liver and intestine was analyzed. Sevelamer treatment significantly reduced liver steatosis and lobular inflammation. Sevelamer-treated NAFLD livers had notably fewer pro-inflammatory infiltrating macrophages and a significantly greater fraction of alternatively activated Kupffer cells compared with controls. Expression of genes involved in FXR signaling in the liver and intestine was significantly altered in mice with NAFLD as well as in those treated with sevelamer. In a mouse model of NAFLD, sevelamer improved disease and counteracted innate immune cell dysregulation in the liver. This study also revealed a dysregulation of FXR signaling in the liver and intestine of NAFLD mice that was counteracted by sevelamer treatment.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Immunity, Innate/drug effects , Intestines/drug effects , Liver/drug effects , Non-alcoholic Fatty Liver Disease/drug therapy , Receptors, Cytoplasmic and Nuclear/metabolism , Sevelamer/administration & dosage , Animals , Disease Models, Animal , Humans , Intestinal Mucosa/metabolism , Liver/metabolism , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/genetics , Non-alcoholic Fatty Liver Disease/immunology , Non-alcoholic Fatty Liver Disease/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...